Company / Operating Income
GT Biopharma, Inc. Operating Income History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$16.1M
FY2020
5-year range
-$9.4M / $16.1M
FY2016-FY2020
Trend
+271.3%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed +271% YoY in FY2020, a notable deviation from the 7-year average annual change of -25%.
Based on SEC 10-K filings.
$16M in FY2020.
Improved from -$9M to $16M over the past 4 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, operating income increased 271.3% year-over-year.
- Lowest operating income in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $16.1M | +271.3% |
| FY2017 | -$9.4M | -5.0% |
| FY2016 | -$8.9M | -272.6% |
| FY2015 | -$2.4M | -202.1% |
| FY2014 | -$793.0K | +77.4% |
| FY2013 | -$3.5M | +10.5% |
| FY2012 | -$3.9M | -57.3% |
| FY2011 | -$2.5M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026